Blood Clotting Disorders

Dear Colleagues,

This Special Issue is dedicated to hemostasis and thrombosis. Hemostasis is a physiologic homeostasis resulting from a dynamic equilibrium between coagulation and fibrinolysis. Several acquired, genetic, and environmental factors can disturb this equilibrium, leading to pathological formation of blood clots in the veins (deep vein thrombosis, DVT), arteries (acute myocardial infarction, ischemic stroke), or heart chambers (left atrial thrombi). Thrombi obstructing blood flow in the deep veins of the legs may dislodge and embolize to cause pulmonary embolism (venous thromboembolism, VTE). Left atrial thrombi can embolize to cause embolic stroke. Coronavirus disease 2019 (COVID-19), caused by a novel strain of coronavirus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), has had massive global economic and health impacts, and was declared a pandemic by the World Health Organization in March 2020. There is evidence of coronavirus-induced cytokine-driven hyperinflammation and immune-mediated activation of coagulation requiring anticoagulant treatment. 

This Special Issue will cover clotting disorders, as well as anticoagulant, antiplatelet, and thrombolytic drugs. The coverage may also include manuscripts on cutting-edge research in the development of new anticoagulants. In order to provide full coverage of blood clotting disorders and anticoagulant drugs, we invite research articles, review papers, and short communications on topics including, but not limited to, those listed below.

We look forward to your contributions.

Dr. Omer Iqbal
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pulmonary embolism
• thrombotic stroke
• deep vein thrombosis
• heparins
• new oral anticoagulants
• sepsis and multiorgan failure
• Stevens Johnson syndrome/toxic epidermal necrolysis
• retinal artery and retinal vein thrombosis
• thrombophilia
• acute myocardial infarction
• left atrial thrombi
• COVID-19-associated thrombosis
• peripheral vascular disease
• heparin-induced thrombocytopenia thrombosis syndrome
• atrial fibrillation
• end-stage renal disease
• cancer-associated thrombosis